Total Debt to Capital: Citius Pharma (CTXR)

The price action of Citius Pharmaceuticals (CTXR) securities reflects a total debt-to-equity ratio of 0.10. Citius Pharmaceuticals is focusing on establishing US distribution networks to independently bring drugs to market. While the business is independent of economic cycles, it remains sensitive to the cost of borrowing. High authority among critical care physicians confirms the effectiveness of their therapeutic approaches to severe hospital conditions.

Citius Pharmaceuticals Inc. (CTXR): Debt to Equity Ratio from 07/04/2022 to 10/29/2026

Citius Pharmaceuticals, Inc. - analytical breakdowns and key metrics (CTXR)

- share price and consensus valuation forecast:

Stock Price Citius Pharmaceuticals Inc.|CTXR - Analyst Target Range

- company stock exchange capitalization indicators:

Market Capitalization Citius Pharmaceuticals|CTXR - Total Enterprise Value

- book capitalization indicators:

Net Assets per Single Share Citius Pharmaceuticals|CTXR - Accounting Capitalization|Market Capitalization to Book Value Ratio citiuspharma.com|CTXR - Company Assets

- issuer credit burden and liquidity indicators:

Debt to Equity Citius Pharmaceuticals|CTXR - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Citius Pharmaceuticals Inc.|CTXR - Company Aggregate Debts|Debt to Book Capitalization Ratio Citius Pharmaceuticals|CTXR - Company Long-Term Debt|Company Current Liabilities Citius Pharmaceuticals|Quick Liquidity citiuspharma.com

- net income and valuation ratios data:

CTXR - Company Net Income

Basic company analysis:CTXR, Citius Pharmaceuticals

Core merchandise of Citius Pharmaceuticals, Inc.

This ratio is indispensable for stress-testing debt loads and assessing the financial stability of a portfolio asset. It measures the proportion of borrowed funds relative to equity, while the debt-to-equity chart for Citius Pharmaceuticals (CTXR) reflects the balance between credit leverage and the stability of revenues from hospital supplies of medications for the treatment of catheter-related infections.

Key competitors